CoChat

Fibroblasts as Modulators of Local and Systemic Cancer Metabolism

Open access

The DOI matches its Crossref record; 113 of the 115 references it cites were found in a registry or an index.

Abstract

Fibroblast activation is an accompanying feature of solid tumor progression, resembling a conserved host response to tissue damage. Cancer-associated fibroblasts (CAFs) comprise a heterogeneous and plastic population with increasingly appreciated roles in tumor growth, metastatic capacity, and response to therapy. Classical features of fibroblasts in a wound-healing response, including profound extracellular matrix production and cytokine release, are recapitulated in cancer. Emerging evidence suggests that fibroblastic cells in the microenvironments of solid tumors also critically modulate cellular metabolism in the neoplastic compartment through mechanisms including paracrine transfer of metabolites or non-cell-autonomous regulation of metabolic signaling pathways. These metabolic functions may represent common mechanisms by which fibroblasts stimulate growth of the regenerating epithelium during a wound-healing reaction, or may reflect unique co-evolution of cancer cells and surrounding stroma within the tumor microenvironment. Here we review the recent literature supporting an important role for CAFs in regulation of cancer cell metabolism, and relevant pathways that may serve as targets for therapeutic intervention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers11050619

Cites

113 of 113 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 CAF secretions of immunomodulatory factors regulate anti-tumor immune response. CAF secretion of CXCL12/SDF1, M-CSF/CSF-1, IL-6, and CCL2/MCP-1 recruits tumor-associated macrophages to the TME and helps differentiate them to an M2 Immunosuppressive phenotype. CXCL1, CXCL2, CXCL5, CXCL6, CXCL8, and CCL2 recruits tumor-associated neutrophils and polarizes them to an N2 pro-tumoral phenotype. CAF and cancer cell secretion of TGF-β induces miR-183 to inhibit DAP12 transcription and reduce natural killer (NK) activating receptors (NKp30, NKp44, NKG2D), while PGE2 and IDO secretion decreases NK cell cytotoxicity against cancer cells. TGF-β also promotes cell death of CD8+ T cells by inhibiting expression of Bcl-2 and causes dendritic cells (DC) to downregulate expression of MHC class II, CD40, CD80, and CD86 leading to decreased antigen presentation efficiency along with decreased production of TNF-α, IFN-γ, and IL-12. TDO2 and IDO1 secretion promotes tryptophan metabolism to kynurenines (Kyn), inhibiting DC differentiation and damages T cell response by catabolizing tryptophan degradation into Kyn, causing T cell anergy and apoptosis through depletion of tryptophan and accumulation of immunosuppressive tryptophan catabolites. VEGF secretion inhibits DC generation and maturation by reducing MHC class II expression and antigen presenting abilities. Secretion of CCL2, CCL5, and CCL17 along with polarizing cytokines IL-1, IL-6, IL-13, and IL-26 switch CD4+ helper T lymphocytes from an anti-tumor TH1 response to a pro-tumor TH2 and TH17 response.
Figure 1 CAF secretions of immunomodulatory factors regulate anti-tumor immune response. CAF secretion of CXCL12/SDF1, M-CSF/CSF-1, IL-6, and CCL2/MCP-1 recruits tumor-associated macrophages to the TME and helps differentiate them to an M2 Immunosuppressive phenotype. CXCL1, CXCL2, CXCL5, CXCL6, CXCL8, and CCL2 recruits tumor-associated neutrophils and polarizes them to an N2 pro-tumoral phenotype. CAF and cancer cell secretion of TGF-β induces miR-183 to inhibit DAP12 transcription and reduce natural killer (NK) activating receptors (NKp30, NKp44, NKG2D), while PGE2 and IDO secretion decreases NK cell cytotoxicity against cancer cells. TGF-β also promotes cell death of CD8+ T cells by inhibiting expression of Bcl-2 and causes dendritic cells (DC) to downregulate expression of MHC class II, CD40, CD80, and CD86 leading to decreased antigen presentation efficiency along with decreased production of TNF-α, IFN-γ, and IL-12. TDO2 and IDO1 secretion promotes tryptophan metabolism to kynurenines (Kyn), inhibiting DC differentiation and damages T cell response by catabolizing tryptophan degradation into Kyn, causing T cell anergy and apoptosis through depletion of tryptophan and accumulation of immunosuppressive tryptophan catabolites. VEGF secretion inhibits DC generation and maturation by reducing MHC class II expression and antigen presenting abilities. Secretion of CCL2, CCL5, and CCL17 along with polarizing cytokines IL-1, IL-6, IL-13, and IL-26 switch CD4+ helper T lymphocytes from an anti-tumor TH1 response to a pro-tumor TH2 and TH17 response.CC BY · PubMed Central
Figure 2 A role for fibroblast-derived metabolites in tumor-stroma interactions. (A) illustrates metabolic reprogramming in CAFs and (B) illustrates the effect of metabolites derived from CAFs to cancer cells in the TME. (1) Activated CAFs uptake excess TME lactate produced by glycolytic cells in the TME. (2) p62 deficient CAFs are autophagy defective and have upregulation of ATF4 which activates metabolic flux through pyruvate carboxylase (PC) → asparagine synthase (ASNS) pathway producing asparagine that is consumed by cancer cells. (3) CAFs characterized by upregulation of anapleurotic glutamine metabolism where cancer cell-derived aspartate, asparagine, and glutamate are used to generate glutamate that is fed to cancer cells; glutamine amino ligase (GLUL) is overexpressed in these CAFs. (4) Cancer cells induce autophagy in CAFs increasing turnover of non-essential amino acids, alanine has been shown to be up-taken by cancer cells to support growth. (5) Upon activation pancreatic and hepatic CAFs shift from lipid storing to lipid-secreting wherein CAF-derived lipids support proliferation and migratory potential of cancer cells. (6) Exosome releasing CAFs pack metabolic molecules used by cancer cells. (7) CAV1 deficient CAFs are known to upregulate glycolytic metabolism, as well as, fibroblast activation by PDGF and TGFβ. (A) describes metabolic alterations in CAFs in dashed boxes. In both figures metabolic pathways are denoted with green arrows, cellular processes are assigned specific colors, and metabolic molecules are underlined.
Figure 2 A role for fibroblast-derived metabolites in tumor-stroma interactions. (A) illustrates metabolic reprogramming in CAFs and (B) illustrates the effect of metabolites derived from CAFs to cancer cells in the TME. (1) Activated CAFs uptake excess TME lactate produced by glycolytic cells in the TME. (2) p62 deficient CAFs are autophagy defective and have upregulation of ATF4 which activates metabolic flux through pyruvate carboxylase (PC) → asparagine synthase (ASNS) pathway producing asparagine that is consumed by cancer cells. (3) CAFs characterized by upregulation of anapleurotic glutamine metabolism where cancer cell-derived aspartate, asparagine, and glutamate are used to generate glutamate that is fed to cancer cells; glutamine amino ligase (GLUL) is overexpressed in these CAFs. (4) Cancer cells induce autophagy in CAFs increasing turnover of non-essential amino acids, alanine has been shown to be up-taken by cancer cells to support growth. (5) Upon activation pancreatic and hepatic CAFs shift from lipid storing to lipid-secreting wherein CAF-derived lipids support proliferation and migratory potential of cancer cells. (6) Exosome releasing CAFs pack metabolic molecules used by cancer cells. (7) CAV1 deficient CAFs are known to upregulate glycolytic metabolism, as well as, fibroblast activation by PDGF and TGFβ. (A) describes metabolic alterations in CAFs in dashed boxes. In both figures metabolic pathways are denoted with green arrows, cellular processes are assigned specific colors, and metabolic molecules are underlined.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 113 references

Cited by

See all 81

Metadata

Authors
Sanford-Crane, H., Abrego, J., & Sherman, M. H.
Affiliations
Oregon Health & Science University (US)
Corresponding author
Sherman, Mara H.
Venue
Cancers
Publisher
MDPI AG
Published
2019-05-03
Volume
11
Issue
5
Pages
619
ISSN
2072-6694 (ISSN-L)
OpenAlex
W2943306398
Cited by
77
References
115
Citations by year
2026: 3 · 2025: 8 · 2024: 5 · 2023: 9 · 2022: 12 · 2021: 17 · 2020: 20 · 2019: 2
FWCI
1.22
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Cancer Institute (CA188259, CA229580)
  • American Cancer Society (132898-RSG-18-142-01-CSM)
  • V Foundation for Cancer Research (V Scholar Award)
  • DOD Peer Reviewed Cancer Research Program (W81XWH-18-1-0437)
  • Hirshberg Foundation for Pancreatic Cancer Research (Seed Grant)
  • Medical Research Foundation (New Investigator Grant)
  • Oregon Health and Science University (Brenden-Colson Center Pilot Award, Cancer Early Detection Advanced Research Pilot Award, Fellowship for Diversity in Research)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
cancer-associated fibroblasts, tumor microenvironment, cancer metabolism, fibroblast activation, extracellular matrix, wound healing, non-cell-autonomous signaling, tumor stroma, metastasis, therapeutic target

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fibroblasts as Modulators of Local and Systemic Cancer Metabolism. https://app.cochat.ai/papers/10.3390/cancers11050619
The paper
Sanford-Crane, H., Abrego, J., & Sherman, M. H. (2019). Fibroblasts as Modulators of Local and Systemic Cancer Metabolism. Cancers. https://doi.org/10.3390/cancers11050619

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.